Methods for inhibiting tumor cell proliferation
The subject invention concerns methods for inhibition of STAT biological functions using platinum complexes.
1. A method for inhibiting function or activity of a STAT transcription factor, comprising contacting a STAT transcription factor with a platinum complex of
or a pharmaceutically-acceptable salt thereof.
2. The method according to claim 1 , wherein said STAT transcription factor is expressed in a cell.
3. The method according to claim 2 , wherein said cell is a tumor cell, cancer cell, or a transformed cell.
4. The method according to claim 2 , wherein said cell is a mammalian cell.
5. The method according to claim 4 , wherein said mammalian cell is a human cell, monkey cell, chimpanzee cell, ape cell, dog cell, cat cell, horse cell, cow cell, or pig cell.
6. The method according to claim 2 , wherein said platinum complex is encapsulated in a liposome moiety or said platinum complex comprises a protein or nucleic acid that targets delivery of the platinum complex to said cell.
7. The method according to claim 1 , wherein said STAT transcription factor is Stat1.
8. A method for treating a cancer or tumor that is aberrantly or constitutively expressing a STAT transcription factor in a human or other animal, comprising administering to the human or other animal an effective amount of a platinum complex of
or a pharmaceutically-acceptable salt thereof.
9. The method according to claim 8 , wherein the other animal is a mammal.
10. The method according to claim 8 , wherein the other animal is monkey, chimpanzee, ape, dog, cat, horse, cow, or pig.
11. The method according to claim 8 , wherein said platinum complex is encapsulated in a liposome moiety or said platinum complex comprises a protein or nucleic acid that targets delivery of the platinum complex to a cell of the person or animal.
12. The method according to claim 11 , wherein said cell is a tumor cell, cancer cell, or transformed cell.
13. The method according to claim 8 , wherein said cancer or tumor is a melanoma, a colon cancer, a breast cancer, or a non-small cell lung cancer.
14. The method according to claim 2 , wherein said cell is a melanoma cell, a colon cancer cell, a breast cancer cell, or a non-small cell lung cancer cell.
15. The method according to claim 2 , wherein said cell constitutively expresses said STAT transcription factor.
16. The method according to claim 2 , wherein apoptosis is induced by said platinum complex in said cell.
17. The method according to claim 1 , wherein said pharmaceutically acceptable salt is an acid addition salt selected from the group consisting of hydrochloric, hydrobromic, nitric, phosphoric, carbonic, sulphuric, acetic, propionic, benzoic, succinic, fumaric, mandelic, oxalic, citric, tartaric, and maleic.
18. The method according to claim 8 , wherein said pharmaceutically acceptable salt is an acid addition salt selected from the group consisting of hydrochloric, hydrobromic, nitric, phosphoric, carbonic, sulphuric, acetic, propionic, benzoic, succinic, fumaric, mandelic, oxalic, citric, tartaric, and maleic.
19. The method according to claim 1 , wherein said pharmaceutically acceptable salt is a base addition salt selected from the group consisting of sodium, potassium, calcium, ammonium, and magnesium.
20. The method according to claim 8 , wherein said pharmaceutically acceptable salt is a base addition salt selected from the group consisting of sodium, potassium, calcium, ammonium, and magnesium.
21. The method according to claim 8 , wherein said platinum complex is administered orally, nasally, rectally, or parenterally.
22. The method according to claim 8 , wherein said platinum complex is administered subcutaneously, intradermally, intravenously, intramuscularly, intraperitoneally, or intrasternally.
23. The method according to claim 8 , wherein said STAT transcription factor is Stat1.